Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| GHK-Cu | Pentadeca Arginate (PDA) | |
|---|---|---|
| Category | Growth Factors | Peptides |
| Standard Dose | Research indicates 1-2 mg daily via subcutaneous injection, or topical application at 1-3% concentration in cream/serum. | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection. |
| Timing | Evening administration preferred for skin rejuvenation (aligns with nocturnal repair cycles). Topical can be applied morning and evening. | Administer on an empty stomach. Inject near site of injury for localized effect. |
| Cycle Duration | 8-12 weeks for injectable cycles. Topical use can be ongoing. | 4-12 weeks depending on therapeutic target. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that modulates gene expression affecting 31.2% of human genes. It activates Wnt/beta-catenin signaling for hair follicle growth, stimulates TGF-beta pathway for tissue remodeling, and promotes collagen and glycosaminoglycan synthesis while modulating metalloproteinase activity. The copper ion serves as a cofactor for enzymes essential to wound healing including superoxide dismutase and lysyl oxidase.
Research indicates 1-2 mg daily via subcutaneous injection, or topical application at 1-3% concentration in cream/serum.
Evening administration preferred for skin rejuvenation (aligns with nocturnal repair cycles). Topical can be applied morning and evening.
8-12 weeks for injectable cycles. Topical use can be ongoing.
Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
Administer on an empty stomach. Inject near site of injury for localized effect.
4-12 weeks depending on therapeutic target.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →